Funding:
This research did not receive any specific grant from funding agencies
in the public, commercial, or not-for-profit sectors. This work was
supported by the Northwestern Medicine Enterprise Data Warehouse under
NIH grant UL1TR001422.
Disclosures : The authors have no disclosures.
References :
1. Brown, J.R., et al., Characterization of atrial fibrillation
adverse events reported in ibrutinib randomized controlled registration
trials. Haematologica, 2017. 102 (10): p. 1796-1805.
2. Lentz, R., et al., Risk factors for the development of atrial
fibrillation on ibrutinib treatment. Leuk Lymphoma, 2019.60 (6): p. 1447-1453.
3. Baptiste, F., et al., High incidence of atrial fibrillation in
patients treated with ibrutinib. Open Heart, 2019. 6 (1): p.
e001049.
4. Leong, D.P., et al., The risk of atrial fibrillation with
ibrutinib use: a systematic review and meta-analysis. Blood, 2016.128 (1): p. 138-40.
5. Salem, J.E., et al., Cardiovascular Toxicities Associated With
Ibrutinib. J Am Coll Cardiol, 2019. 74 (13): p. 1667-1678.
6. Wiczer, T.E., et al., Cumulative incidence, risk factors, and
management of atrial fibrillation in patients receiving ibrutinib.Blood Adv, 2017. 1 (20): p. 1739-1748.
7. Reda, G., et al., Predictors of atrial fibrillation in
ibrutinib-treated CLL patients: a prospective study. J Hematol Oncol,
2018. 11 (1): p. 79.
8. Cameli, M., et al., Left atrial strain: a new parameter for
assessment of left ventricular filling pressure. Heart Fail Rev, 2016.21 (1): p. 65-76.
9. Pathan, F., et al., Normal Ranges of Left Atrial Strain by
Speckle-Tracking Echocardiography: A Systematic Review and
Meta-Analysis. J Am Soc Echocardiogr, 2017. 30 (1): p. 59-70
e8.
10. Cameli, M., et al., Feasibility and reference values of left
atrial longitudinal strain imaging by two-dimensional speckle tracking.Cardiovasc Ultrasound, 2009. 7 : p. 6.
11. Cameli, M., et al., Left atrial strain: A useful index in
atrial fibrillation. Int J Cardiol, 2016. 220 : p. 208-13.
12. Lang, R.M., et al., Recommendations for cardiac chamber
quantification by echocardiography in adults: an update from the
American Society of Echocardiography and the European Association of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging, 2015.16 (3): p. 233-70.
13. Thorp, B.C. and X. Badoux, Atrial fibrillation as a
complication of ibrutinib therapy: clinical features and challenges of
management. Leuk Lymphoma, 2018. 59 (2): p. 311-320.
14. McMullen, J.R., et al., Ibrutinib increases the risk of atrial
fibrillation, potentially through inhibition of cardiac PI3K-Akt
signaling. Blood, 2014. 124 (25): p. 3829-30.
15. Jiang, L., et al., Ibrutinib promotes atrial fibrillation by
inducing structural remodeling and calcium dysregulation in the atrium.Heart Rhythm, 2019.
16. Nemes, A., et al., Is three-dimensional speckle-tracking
echocardiography able to identify different patterns of left atrial
dysfunction in selected disorders?: Short summary of the MAGYAR-Path
Study. Int J Cardiol, 2016. 220 : p. 535-7.
17. Negishi, K., et al., Left atrial booster pump function is an
independent predictor of subsequent life-threatening ventricular
arrhythmias in non-ischaemic cardiomyopathy. Eur Heart J Cardiovasc
Imaging, 2016. 17 (10): p. 1153-60.
18. Shih, J.Y., et al., Association of decreased left atrial
strain and strain rate with stroke in chronic atrial fibrillation. J Am
Soc Echocardiogr, 2011. 24 (5): p. 513-9.
19. Shaikh, A.Y., et al., Speckle echocardiographic left atrial
strain and stiffness index as predictors of maintenance of sinus rhythm
after cardioversion for atrial fibrillation: a prospective study.Cardiovasc Ultrasound, 2012. 10 : p. 48.
20. Tops, L.F., et al., Left atrial strain predicts reverse
remodeling after catheter ablation for atrial fibrillation. J Am Coll
Cardiol, 2011. 57 (3): p. 324-31.
21. Ganatra, S., et al., Ibrutinib-Associated Atrial
Fibrillation. JACC Clin Electrophysiol, 2018. 4 (12): p.
1491-1500.
22. Khalid, S., et al., Management of Atrial Fibrillation in
Patients on Ibrutinib: A Cleveland Clinic Experience. Cureus, 2018.10 (5): p. e2701.
23. Boriani, G., et al., Practical management of ibrutinib in the
real life: Focus on atrial fibrillation and bleeding. Hematol Oncol,
2018. 36 (4): p. 624-632.
24. Chai, K.L., et al., Practical recommendations for the choice
of anticoagulants in the management of patients with atrial fibrillation
on ibrutinib. Leuk Lymphoma, 2017. 58 (12): p. 2811-2814.